<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2653956&amp;fmt=gif">
Image Overlay - FDA Recommends Approval of Peanut Allergy Medicine
Image Overlay - FDA Recommends Approval of Peanut Allergy Medicine

FDA Recommends Approval of Peanut Allergy Medicine

FDA Recommends Approval of Peanut Allergy Medicine

Aimmune has developed a new oral immunotherapy designed to enable peanut allergy sufferers to avoid serious allergic reactions if exposed to minor quantities of peanut protein. Palforzia (previously AR101) is a peanut-derived biologic that delivers a daily dose of peanut protein with a consistent protein profile, analyzed to ensure reliable major allergen content. Regular consumption of Palforzia is intended to reduce allergic reactions. There are no treatments for peanut allergy approved by the U.S. Food and Drug Administration (FDA), but that may soon change. Yourway keeps the supply chain moving. We are able to seamlessly manage any inventory through our easy-to-use client portal.

Back to Index
Stay Connected

Want to stay informed about the latest news, updates, and opportunities at Yourway?

Join our newsletter mailing list to never miss an update!

Media

Upcoming Events

Clinical Trial Supply Europe

February 24-26, 2026
Hyatt Regency, Barcelona Tower

Global Clinical Supplies Group Asia Pacific Conference

March 10-12, 2026
Conrad Seoul Hotel, South Korea

Media

Articles

Why Integration Matters in Clinical Supply Chains

Open chat
Come chat with us!
Hello! How can I help you?